Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD‐L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer

BACKGROUND: We examined the current biomarker landscape in breast cancer when programmed death‐ligand 1 (PD‐L1) testing is integrated with comprehensive genomic profiling (CGP). MATERIAL AND METHODS: We analyzed data from samples of 312 consecutive patients with breast carcinoma tested with both CGP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Huang, Richard S.P., Li, Xinyan, Haberberger, James, Sokol, Ethan, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Williams, Erik, Elvin, Julia, Vergilio, Jo‐Anne, Killian, Jonathan Keith, Lin, Douglas, Hiemenz, Matthew, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Danziger, Natalie, Erlich, Rachel, Frampton, Garrett, Cohen, Michael B., McGregor, Kimberly, Reddy, Prasanth, Cardeiro, Dawn, Anhorn, Rachel, Venstrom, Jeffrey, Alexander, Brian, Brown, Charlotte, Pusztai, Lajos, Ross, Jeffrey S., Ramkissoon, Shakti H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Cancer Diagnostics and Molecular Pathology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648336/
https://ncbi.nlm.nih.gov/pubmed/32869930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados